<span item_type="fundamental" item_id="ac34a76be3ac0e0cf5ce7fe5b8895c57" counter_id="ST/US/RXST" env="prod"></span><span item_type="announcement" item_id="604185020915784961" env="prod"></span><p>Revenue: As of FY2025 Q4, the actual value is USD 32.6 M, beating the estimate of USD 27.53 M.</p><p></p><h3>Revenue</h3><ul><li><strong>Fourth Quarter 2025 Revenue</strong>: Approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®) and 25 Light Delivery Devices (LDD™s).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-ex99_1.htm"></span></li><li><strong>Full-year 2025 Revenue</strong>: Approximately $134.5 million, exceeding the November guidance of $125 to $130 million, driven by the sale of 109,615 LALs and 163 LDDs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-ex99_1.htm"></span></li></ul><h3>Cash Position</h3><ul><li><strong>Cash, Cash Equivalents, and Short-term Investments</strong>: Expected to be $228.1 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Audited full-year 2025 financial results and full-year 2026 guidance will be announced in conjunction with the company’s fourth quarter earnings release in February 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-ex99_1.htm"></span></li></ul>

RxSight | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 32.6 M